Evaluating the Risk of Major Adverse Limb Events and Antithrombotic Therapy in PAD Patients
| Overview / Abstract: |
Patients who experience a cardiovascular event and/or have peripheral artery disease require long-term antithrombotic prophylaxis to reduce the risk of recurrent cardiac events. Formulating complex regimens for secondary prevention of subsequent cardiovascular events and improved long-term cardiovascular outcomes poses a significant clinical challenge, and patients continue to experience events and associated mortality. The purpose of this activity is to review past and current clinical trial evidence investigating anticoagulant use as monotherapy or in combination regimens with antiplatelet therapy for the reduction of thrombotic events in diverse cardiovascular patients. |
|
Expiration |
May 31, 2020 |
|
Discipline(s) |
Nurse Practitioner , Nursing CNE, Physician CME, Physician Assistant CME |
|
Format |
Webinar / Webcast / Video |
|
Credits / Hours |
.75 AMA PRA Category 1 Credit(s)™ |
|
Accreditation |
ACCME |
|
Presenters / Authors / Faculty |
Marc Bonaca, MD, MPH and Christian Ruff, MD |
|
Activity Specialities / Related Topics |
Acute Care, Anticoagulation / Thrombosis, Cardiology / Cardiovascular, Critical Care / Intensive Care, Diagnosis / Assessment / Patient History, Family Medicine, Internal Medicine |
|
Sponsors / Supporters / Grant Providers |
Supported by an educational grant from Janssen Scientific Affairs, LLC |
|
Keywords / Search Terms |
ACHL DOAC, DOACs, NOACs, NOAC, PAD, CAD, peripheral, arterial, anticoagulants, anticoagulation, antiplatelet, aspirin, DAPT, Christian Ruff, Marc Bonaca, VTE, thrombosis, Oral anticoagulation, Atrial fibrillation, Stroke, Venous thromboembolism, Bleeding, Dabigatran (Pradaxa) BI, rivaroxaban (Xarelto) Janssen, apixaban (Eliquis) BMS/Pfizer, edoxaban (Savaysa) Daiichi-Sankyo, stable atherosclerotic vascular disease, stable Free CE CME |
|